Pyxis Oncology, Inc.

PYXS

$2.63

$-0.22 (-7.72%)

Closed

Loading chart...

IndexN/A

Market Cap0.17B

Enterprise Value0.07B

Income$-0.02B

Sales$0.00B

EmployeesN/A

P/E-2.01

P/S5.16

P/B1.34

P/C-1.13

EV/EBITDA-1.01

EV/SalesN/A

EPS (ttm)-1.31

EarningsN/A

Gross Margin82.77%

Oper. Margin-609.18%

Profit Margin-574.55%

Volume0.69M

Shs Outstand0.06B

Change-7.72%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 3007:30AMPyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones(globenewswire.com)

May 1407:00AMPyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones(globenewswire.com)

May 1307:30AMPyxis Oncology to Participate in Upcoming Investor Conferences(globenewswire.com)

May 704:05PMPyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

Insider Trading

View All

Insider

Type

Price

Value

Date

Dupont Jakob

Option

35.0K

$1.60

$56K

Jun 30, 26

Dupont Jakob

Sell

35.0K

$3.06

$107K

Jun 30, 26

Palani Santhosh

Award

45.9K

$1.36

$62K

Mar 24, 26

HUMPHREY RACHEL

Award

45.9K

$1.36

$62K

Mar 24, 26

Cline Darren S

Award

45.9K

$1.36

$62K

Mar 24, 26

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

CEO: Thomas CivikEmployees: 44www.pyxisoncology.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$16.15M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$475.00K	N/A	N/A	N/A	$444.00K	N/A
Gross Profit	$15.67M	N/A	N/A	N/A	$-444.00K	N/A
Gross Margin	97.06%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$105.13M	$82.20M	$123.48M	$69.72M	$12.45M	$2.88M
Operating Income	$-89.46M	$-82.20M	$-123.48M	$-69.72M	$-12.89M	$-2.88M
Operating Margin	-554.07%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-77.33M	$-73.79M	$-120.72M	$-75.97M	$-12.83M	$-2.77M
Net Margin	-478.95%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-1.32	$-1.85	$-3.57	$-2.53	$-0.37	$-0.08
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A

Pyxis Oncology, Inc.

Insider Trading

Discover more